Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1774364
PUBLISHER: BCC Research | PRODUCT CODE: 1774364
Global Markets for Infectious Disease Treatments
PUBLISHED:
PAGES: 186 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global market for infectious disease treatments is expected to grow from $72.5 billion in 2025 and is projected to reach $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030.
The North American market for infectious disease treatments is expected to grow from $39.9 billion in 2025 and is projected to reach $54.7 billion by the end of 2030, at a CAGR of 6.5% during the forecast period of 2025 to 2030.
The European market for infectious disease treatments is expected to grow from $13.5 billion in 2025 and is projected to reach $17.7 billion by the end of 2030, at a CAGR of 5.6% during the forecast period of 2025 to 2030.
Report Scope
This report offers an analysis of the global market for infectious disease therapeutics, vaccines, and diagnostics. The infectious diseases covered in the report include human immunodeficiency virus (HIV) infection, seasonal influenza (including influenza A and B), hepatitis B, hepatitis C, respiratory syncytial virus (RSV) infection, tuberculosis (TB), herpes simplex virus (HSV) infection, malaria, rotavirus infection, and viral hemorrhagic fevers such as yellow fever, dengue, Lassa fever, Ebola fever, and Zika fever.
The report's estimates of the infectious disease market include global revenue ($ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030. The report focuses on the major trends, challenges and opportunities in the market and vendor landscape. It also covers the new products, acquisitions, and collaborations related to the market. The report also analyzes environmental, social, and corporate governance (ESG) developments.
The report concludes with an analysis of the competitive landscape, which provides a ranking by market share of leading companies in the market. There is also a section of profiles of the leading companies.
Outside the scope of the report are vector/mosquito control approaches, strategies and products, drugs used for symptomatic treatment and not for the elimination of the virus from the host, and details on suppliers of generics and non-branded generics. Also excluded are markets for hospital-based diagnosis that are not carried out by kits (for example, malaria slide smear-based tests), as well as discussion of the spread of vector-borne infection (such as malaria) via blood transfusion.
Report Includes
- 53 data tables and 69 additional tables
- A review of the global market for infectious disease treatments in the healthcare and pharmaceutical industry
- Analyses of the global market trends, with sales data from 2022-2024, estimates for 2025, and projected CAGRs through 2030
- Evaluation and forecast of the overall market size in terms of dollar value terms, and corresponding market share analysis based on product type, disease type, and geographic region
- An evaluation of the market potential for infectious disease treatments, opportunities and gaps, estimating current and future demand
- Discussion of new drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits that are recently launched or in development
- Review of key patent grants and new technologies related to innovations in infectious disease treatments
- Identification of challenges and discussion of how to overcome these to be able to reach commercialization potential, and ESG trends of the market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Profiles of the leading companies, including Gilead Sciences Inc., GSK plc., Sanofi, Merck & Co. Inc., and Abbott
Product Code: PHM061F
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics
- Emerging Trends
- Analysis by Segment
- Analysis by Region
- Conclusion
Chapter 2 Market Overview
- Infectious Diseases
- Management of Infectious Diseases
- Antimicrobial Resistance
- Disease Overviews
- Human Immunodeficiency Virus
- Influenza
- Hepatitis
- Respiratory Syncytial Virus
- Tuberculosis
- Herpes Simplex Virus
- Malaria
- Rotavirus
- Viral Hemorrhagic Fevers-Yellow Fever
- Viral Hemorrhagic Fevers-Dengue
- Viral Hemorrhagic Fevers-Lassa Fever
- Viral Hemorrhagic Fevers-Ebola Fever
- Viral Hemorrhagic Fevers-Zika Virus
- Analysis of Macroeconomic Factors
- Impact of U.S. Tariffs on the Pharmaceutical Industry
- Global Economic Growth
- Demographic Trends
- Porter's Five Forces Analysis
- Bargaining Power of Buyers (Moderate to High)
- Bargaining Power of Suppliers (Moderate to Low)
- Threat of New Entrants (Moderate to Low)
- Threat of Substitutes (Low)
- Level of Competitiveness (High)
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Resistance to Drugs
- Global Efforts to Combat Infectious Diseases
- Technological Advances
- Climate Change
- International Travel
- Market Restraints
- Loss of Exclusivity and Genericization
- Pricing Pressures
- Lack of Awareness and Underdiagnosis
- Market Trends
- Long-acting Injectable Medicines
- Self-Testing Kits
Chapter 4 Regulatory Landscape
- Regulatory Aspects
- U.S.
- European Union
- Japan
- Regulatory Aspects of Infectious Disease Diagnostics
- U.S.
- EU
- Japan
Chapter 5 Emerging Technologies and Developments
- Emerging Technologies
- Multiplex PCR Syndromic Testing
- NGS and Genetic Medicine
- Pipeline Analysis
- Takeaways
- Novel Therapeutic Agents in Phase 3 Development
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Global Infectious Disease Treatment Market, by Product
- Therapeutics
- Vaccines
- Diagnostics
- Global Infectious Disease Treatment Market, by Disease
- HIV/AIDS
- Influenza
- Hepatitis B
- Hepatitis C
- Respiratory Syncytial Virus
- Tuberculosis
- Herpes Simplex Virus
- Malaria
- Rotavirus
- Viral Hemorrhagic Fevers
- Geographic Breakdown
- Global Infectious Disease Treatment Market, by Region
- North America
- Europe
- Asia-Pacific
- Middle East and Africa (MEA)
- South America
Chapter 7 Competitive Intelligence
- Overview
- Infectious Disease Therapeutics Market Shares
- Infectious Disease Vaccines Market Share Analysis
- Infectious Disease Diagnostics Market Ranking
Chapter 8 Sustainability in Infectious Disease Treatment Industry: An ESG Perspective
- Introduction to ESG
- ESG Issues Specific to the Infectious Disease Treatment Market
- Global Health Access and Equity
- R&D for Neglected and Emerging Infectious Diseases
- Antimicrobial Stewardship
- Collaborations with Public Health Bodies
- Concluding Remarks
Chapter 9 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- ABBOTT
- ABBVIE INC.
- CSL
- DANAHER CORP.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- GSK PLC
- JOHNSON & JOHNSON SERVICES INC.
- MERCK & CO. INC.
- MOLBIO DIAGNOSTICS LTD.
- ORASURE TECHNOLOGIES INC.
- PFIZER INC.
- SANOFI
- SERUM INSTITUTE OF INDIA PVT. LTD.
- SIEMENS HEATHINEERS AG
- Emerging Start-ups/Market Disruptors
Product Code: PHM061F
List of Tables
- Summary Table : Global Market for Infectious Disease Treatments, by Region, Through 2030
- Table 1 : Number of New HIV Infections, 2000-2023
- Table 2 : Confirmed Cases of Influenza, by Country, 2022-2024
- Table 3 : Hepatitis Types
- Table 4 : Types of Orthoebolaviruses Causing Disease
- Table 5 : Agencies Driving Global Infectious Disease Initiatives
- Table 6 : WHO-Prequalified Rapid Diagnostic Self-Tests, 2022-2025
- Table 7 : Companies Developing Therapeutics Based on Epigenome Editing Platforms
- Table 8 : Novel Therapeutic Candidates in Phase 3 Clinical Trials
- Table 9 : Global Market for Infectious Disease Treatments, by Product, Through 2030
- Table 10 : Global Market for Infectious Disease Therapeutics, by Disease, Through 2030
- Table 11 : Global Market for Infectious Disease Vaccines, by Disease, Through 2030
- Table 12 : Global Market for Infectious Disease Diagnostics, by Disease, Through 2030
- Table 13 : Global Market for Infectious Disease Treatments, by Disease, Through 2030
- Table 14 : Global Market for HIV Therapeutics, by Region, Through 2030
- Table 15 : WHO-Prequalified HIV Assays, as of December 2024
- Table 16 : HIV Assays Prequalified by the WHO, 2022-2024
- Table 17 : Global Market for HIV Diagnostics, by Region, Through 2030
- Table 18 : Types of Influenza Vaccines
- Table 19 : Global Market for Influenza Vaccines, by Region, Through 2030
- Table 20 : Influenza Virus Testing Methods
- Table 21 : Global Market for Influenza Diagnostics, by Region, Through 2030
- Table 22 : Global Market for Hepatitis B Therapeutics, by Region, Through 2030
- Table 23 : FDA-Approved Hepatitis Vaccines for Commercial Use
- Table 24 : Global Market for Hepatitis B Vaccines, by Region, Through 2030
- Table 25 : WHO-Prequalified HBV Assays, as of December 2024
- Table 26 : Global Market for Hepatitis B Diagnostics, by Region, Through 2030
- Table 27 : Global Market for Hepatitis C Therapeutics, by Region, Through 2030
- Table 28 : WHO-Prequalified HCV Assays, as of December 2024
- Table 29 : Global Market for Hepatitis C Diagnostics, by Region, Through 2030
- Table 30 : FDA-Approved RSV Vaccines
- Table 31 : Global Market for RSV Vaccines, by Region, Through 2030
- Table 32 : Global Market for RSV Diagnostics, by Region, Through 2030
- Table 33 : Global Market for TB Therapeutics, by Region, Through 2030
- Table 34 : Tuberculosis IVDs
- Table 35 : Global Market for TB Diagnostics, by Region, Through 2030
- Table 36 : Global Market for HSV Therapeutics, by Region, Through 2030
- Table 37 : Global Market for HSV Diagnostics, by Region, Through 2030
- Table 38 : Global Market for Malaria Therapeutics, by Region, Through 2030
- Table 39 : Global Market for Malaria Vaccines, by Region, Through 2030
- Table 40 : WHO-Prequalified Malaria RDTs, as of December 2024
- Table 41 : Global Market for Malaria Diagnostics (RDTs*), by Region, Through 2030
- Table 42 : FDA-Approved Rotavirus Vaccines
- Table 43 : Global Market for Rotavirus Vaccines, by Region, Through 2030
- Table 44 : Global Market for Rotavirus Diagnostics, by Region, Through 2030
- Table 45 : Global Market for Yellow Fever Vaccines, by Region, Through 2030
- Table 46 : Approved Dengue Vaccines
- Table 47 : Global Market for Dengue Vaccines, by Region, Through 2030
- Table 48 : Ebola Viral Disease Vaccines
- Table 49 : Global Market for Infectious Disease Treatments, by Region, Through 2030
- Table 50 : North American Market for Infectious Disease Treatments, by Product, Through 2030
- Table 51 : North American Market for Infectious Disease Treatments, by Country, Through 2030
- Table 52 : European Market for Infectious Disease Treatments, by Product, Through 2030
- Table 53 : European Market for Infectious Disease Treatments, by Country, Through 2030
- Table 54 : Asia-Pacific Market for Infectious Disease Treatments, by Product, Through 2030
- Table 55 : Asia-Pacific Market for Infectious Disease Treatments, by Country, Through 2030
- Table 56 : MEA Market for Infectious Disease Treatments, by Product, Through 2030
- Table 57 : South American Market for Infectious Disease Treatments, by Product, Through 2030
- Table 58 : Infectious Disease Diagnostics Market Ranking
- Table 59 : ESG Factors Specific to the Infectious Disease Treatment Industry
- Table 60 : Access to Medicine Index, 2024
- Table 61 : Projects in the Pipeline for Neglected Tropical Diseases, 2024
- Table 62 : Information Sources for this Report
- Table 63 : Abbreviations Used in This Report
- Table 64 : Abbott: Company Snapshot
- Table 65 : Abbott: Financial Performance, FY 2023 and 2024
- Table 66 : Abbott: Product Portfolio
- Table 67 : Abbott: News/Key Developments, 2023 and 2024
- Table 68 : AbbVie Inc.: Company Snapshot
- Table 69 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
- Table 70 : AbbVie Inc.: Product Portfolio
- Table 71 : CSL: Company Snapshot
- Table 72 : CSL: Financial Performance, FY 2022 and 2023
- Table 73 : CSL: Product Portfolio
- Table 74 : CSL: News/Key Developments, 2023 and 2024
- Table 75 : Danaher Corp.: Company Snapshot
- Table 76 : Danaher Corp.: Financial Performance, FY 2023 and 2024
- Table 77 : Danaher Corp.: Product Portfolio
- Table 78 : Danaher Corp: News/Recent Developments, 2023-2025
- Table 79 : F. Hoffmann-La Roche Ltd.: Company Snapshot
- Table 80 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
- Table 81 : F. Hoffmann-La Roche Ltd.: Product Portfolio
- Table 82 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024 and 2025
- Table 83 : Gilead Sciences Inc.: Company Snapshot
- Table 84 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
- Table 85 : Gilead Sciences Inc.: Product Portfolio
- Table 86 : Gilead Sciences Inc.: News/Key Developments, 2024
- Table 87 : GSK plc: Company Snapshot
- Table 88 : GSK plc: Financial Performance, FY 2023 and 2024
- Table 89 : GSK plc: Product Portfolio
- Table 90 : GSK plc: News/Key Developments, 2024 and 2025
- Table 91 : Johnson & Johnson Services Inc.: Company Snapshot
- Table 92 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
- Table 93 : Johnson & Johnson Services Inc.: Product Portfolio
- Table 94 : Johnson & Johnson Services Inc.: News/Key Developments, 2023 and 2024
- Table 95 : Merck & Co. Inc.: Company Snapshot
- Table 96 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
- Table 97 : Merck & Co. Inc.: Product Portfolio
- Table 98 : Merck & Co. Inc.: News/Key Developments, 2023-2025
- Table 99 : Molbio Diagnostics Ltd.: Company Snapshot
- Table 100 : Molbio Diagnostics Ltd.: Product Portfolio
- Table 101 : Molbio Diagnostics Ltd.: News/Key Developments, 2023
- Table 102 : OraSure Technologies Inc.: Company Snapshot
- Table 103 : OraSure Technologies Inc.: Financial Performance, FY 2023 and 2024
- Table 104 : OraSure Technologies Inc.: Product Portfolio
- Table 105 : OraSure Technologies Inc.: News/Key Developments, 2024 and 2025
- Table 106 : Pfizer Inc.: Company Snapshot
- Table 107 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
- Table 108 : Pfizer Inc.: Product Portfolio
- Table 109 : Pfizer Inc.: News/Key Developments, 2024
- Table 110 : Sanofi: Company Snapshot
- Table 111 : Sanofi: Financial Performance, FY 2023 and 2024
- Table 112 : Sanofi: Product Portfolio
- Table 113 : Sanofi: News/Key Developments, 2023-2025
- Table 114 : Serum Institute of India Pvt. Ltd.: Company Snapshot
- Table 115 : Serum Institute of India Pvt. Ltd.: Product Portfolio
- Table 116 : Serum Institute of India Pvt. Ltd.: News/Key Developments, 2024 and 2025
- Table 117 : Siemens Healthineers AG: Company Snapshot
- Table 118 : Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
- Table 119 : Siemens Healthineers AG: Product Portfolio
- Table 120 : Siemens Healthineers AG: News/Key Developments, 2023
- Table 121 : Emerging Startups/Market Disruptors
List of Figures
- Summary Figure : Global Market Shares of Infectious Disease Treatments, by Region, 2024
- Figure 1 : Global Percentage of People Living with HIV, by WHO Region, 2023
- Figure 2 : Global Incidence of Tuberculosis, 2018-2023
- Figure 3 : Global Deaths Due to Tuberculosis, 2018-2023
- Figure 4 : Global Trends in Malaria Incidence and Mortality Cases, 2000-2023
- Figure 5 : Global Estimated Malaria Cases and Deaths, 2019-2023
- Figure 6 : Porter's Five Forces Analysis
- Figure 7 : Market Dynamics
- Figure 8 : Phase 2 and 3 Clinical Trials for Selected Infectious Diseases, March 2025
- Figure 9 : Global Market Shares of Infectious Disease Treatments, by Product, 2024
- Figure 10 : Global Market Shares of Infectious Disease Therapeutics, by Disease, 2024
- Figure 11 : Global Market Shares of Infectious Disease Vaccines, by Disease, 2024
- Figure 12 : Global Market Shares of Infectious Disease Diagnostics, by Disease, 2024
- Figure 13 : Global Market Shares of Infectious Disease Treatments, by Disease, 2024
- Figure 14 : Global Market Shares of HIV Therapeutics, by Region, 2024
- Figure 15 : Global Market Shares of HIV Diagnostics, by Region, 2024
- Figure 16 : Global Market Shares of Influenza Vaccines, by Region, 2024
- Figure 17 : Global Market Shares of Influenza Diagnostics, by Region, 2024
- Figure 18 : Global Market Shares of Hepatitis B Therapeutics, by Region, 2024
- Figure 19 : Global Market Shares of Hepatitis B Vaccines, by Region, 2024
- Figure 20 : Global Market Shares of Hepatitis B Diagnostics, by Region, 2024
- Figure 21 : Global Market Shares of Hepatitis C Therapeutics, by Region, 2024
- Figure 22 : Global Market Shares of Hepatitis C Diagnostics, by Region, 2024
- Figure 23 : Global Market Shares of RSV Vaccines, by Region, 2024
- Figure 24 : Global Market Shares of RSV Diagnostics, by Region, 2024
- Figure 25 : Global Market Shares of TB Therapeutics, by Region, 2024
- Figure 26 : Global Market Shares of TB Diagnostics, by Region, 2024
- Figure 27 : Global Market Shares of HSV Therapeutics, by Region, 2024
- Figure 28 : Global Market Shares of HSV Diagnostics, by Region, 2024
- Figure 29 : Global Market Shares of Malaria Therapeutics, by Region, 2024
- Figure 30 : Global Market Shares of Malaria Diagnostics (RDTs*), by Region, 2024
- Figure 31 : Global Market Shares of Rotavirus Vaccines, by Region, 2024
- Figure 32 : Global Market Shares of Rotavirus Diagnostics, by Region, 2024
- Figure 33 : Global Market Shares of Yellow Fever Vaccines, by Region, 2024
- Figure 34 : Global Market Shares of Dengue Vaccines, by Region, 2024
- Figure 35 : Global Market Shares of Infectious Disease Treatments, by Region, 2024
- Figure 36 : North American Market Shares of Infectious Disease Treatments, by Product, 2024
- Figure 37 : North American Market Shares of Infectious Disease Treatments, by Country, 2024
- Figure 38 : Number of Deaths Due to Infectious and Parasitic Diseases in Mexico, 2021
- Figure 39 : European Market Shares of Infectious Disease Treatments, by Product, 2024
- Figure 40 : European Market Shares of Infectious Disease Treatments, by Country, 2024
- Figure 41 : Asia-Pacific Market Shares of Infectious Disease Treatments, by Product, 2024
- Figure 42 : Asia-Pacific Market Shares of Infectious Disease Treatments, by Country, 2024
- Figure 43 : MEA Market Shares of Infectious Disease Treatments, by Product, 2024
- Figure 44 : South American Market Shares of Infectious Disease Treatments, by Product Type, 2024
- Figure 45 : Global Market Shares of Infectious Disease Therapeutics, by Company, 2024
- Figure 46 : Global Market Shares of Infectious Disease Vaccines, by Company, 2024
- Figure 47 : Abbott: Revenue Shares, by Business Unit, FY 2024
- Figure 48 : Abbott: Revenue Shares, by Country/Region, FY 2024
- Figure 49 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 50 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 51 : CSL: Revenue Shares, by Business Unit, FY 2023
- Figure 52 : CSL: Revenue Shares, by Country/Region, FY 2023
- Figure 53 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2024
- Figure 54 : Danaher Corp: Revenue Shares, by Region/Country, FY 2024
- Figure 55 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
- Figure 56 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
- Figure 57 : Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 58 : Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 59 : GSK plc: Revenue Shares, by Business Unit, FY 2024
- Figure 60 : GSK plc: Revenue Shares, by Country/Region, FY 2024
- Figure 61 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 62 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 63 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 64 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 65 : OraSure Technologies Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 66 : OraSure Technologies Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 67 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 68 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 69 : SANOFI: Revenue Shares, by Business Unit, FY 2024
- Figure 70 : SANOFI: Revenue Shares, by Country/Region, FY 2024
- Figure 71 : Siemens Healthineers AG: Revenue Shares, by Business Unit, FY 2024
- Figure 72 : Siemens Healthineers AG: Revenue Shares, by Country/Region, FY 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.